Close

Biotech President Sees More Medical Breakthroughs And Good Investment Opportunities Ahead

NEW YORK, N.Y., (February 24, 1999) -- Twenty-one new biotechnology drugs, vaccines and new indications for existing drugs were approved by the Food and Drug Administration (FDA) in 1998.

...

BIO Responds To Bt Lawsuit

...

Price Controls Promise Only To Undermine Biotech Drug Development

...

Women's Health Issues Explored At BIO CEO & Investor Conference

...

52 Companies To Make Presentations At BIO's Annual CEO & Investor Conference

...

BIO Statement on Iceland Genetic Data

...

Canada's Decision on BST Counters FDA, WHO, AMA Views

...

BIO Statement Regarding Commercial Development of Pluripotent Stem Cells

To the Subcommittee on Labor, Health and Human Services, Education of the Senate Appropriations Committee

BIO Urges President's Bioethics Advisory Panel To Consider Issues Raised By Stem Cell Research

Carl B Feldbaum, president of BIO, today issued the following statement on the need for national discussion based on the ethical implications of recent research breakthroughs involving primordial human stem cells...

BIO CEO & Investor Conference Presentations Target Specific Diseases, Therapies

...